Volume 13, Issue 4 (Autumn 2024)
aumj 2024, 13(4): 290-294 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abbasi Khoshsirat N, Samimisedeh P. 44-year-old Female Patient with Multiple Sclerosis (MS) being treated with Rituximab who has also tested positive for Covid-19. aumj 2024; 13 (4) :290-294
URL: http://aums.abzums.ac.ir/article-1-1203-en.html
URL: http://aums.abzums.ac.ir/article-1-1203-en.html
1- Cardiovascular Research Center, Alborz University of Medical Sciences, Karaj, Iran
2- Rajaei Clinical Research Development Unit,Alborz University of Medical Sciences, Karaj, Iran
2- Rajaei Clinical Research Development Unit,Alborz University of Medical Sciences, Karaj, Iran
Abstract: (240 Views)
In March 2020, the World Health Organization announced that the disease caused by the SARS-COV-2 virus (COVID-19) had become a pandemic. This virus was first identified in Wuhan, China. Among the high-risk groups during the COVID-19 pandemic are individuals with multiple sclerosis (MS). Many experienced practitioners in the treatment of MS have noted that it is still unclear whether MS treatment with medication affects the susceptibility to or the clinical severity of COVID-19 infection. However, based on most current articles, medications with the highest levels of immunosuppression (such as CD-20 inhibitors like Rituximab) are likely not suitable for treating MS patients during the COVID-19 epidemic, although there is no scientific evidence to prove this. This study examines a 44-year-old woman with known MS who was treated with Zytux (Rituximab) and received her last dose in early February 2020, coinciding with the onset of the COVID-19 epidemic. On March 21, 2020, less than a month after the injection, she presented with symptoms of cough, fever, and myalgia, and was ultimately diagnosed with COVID-19. The patient was hospitalized and died during admission due to respiratory failure.
Type of Study: Case Report |
Subject:
Special
Received: 2020/10/21 | Accepted: 2022/09/12 | Published: 2024/11/30
Received: 2020/10/21 | Accepted: 2022/09/12 | Published: 2024/11/30
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
